Effects of trimetazidine combined with metoprolol on serum indexes and quality of life in patients with heart failure due to ischemic cardiomyopathy
Objective To analyze the effects of trimetazidine combined with metoprolol in the treatment of patients with heart failure due to ischemic cardiomyopathy(ICM).Methods Ninety-eight patients with heart failure due to ICM admitted from April 2019 to April 2021 were selected as the study objects and divided into control group(n=49,metoprolol)and study group(n=49,trimetazidine+metoprolol)according to random number table method.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the study group was higher than that in the control group(P<0.05).After treatment,the total ischemic load,total ischemic frequency,ischemic duration and maximum ST segment shift of the two groups reduced or shortened,and those in the study group were better than the control group(P<0.05).After treatment,the levels of N-terminal pro-brain natriuretic peptide(NT-proBNP),matrix metalloproteinase-2(MMP-2),soluble suppression of tumorigenicity 2(sST2)and galectin-3(Gal-3)in both groups decreased,and those in the study group were lower than the control group(P<0.05).After treatment,the scores of each dimension of the 36-Item Short Form Health Survey(SF-36)in both groups improved,and those in the study group were higher than the control group(P<0.05).Conclusion Trimetazidine combined with metoprolol has a significant effect in the treatment of heart failure due to ICM,it can not only improve the serum indexes and myocardial microcirculation of patients,but also improve the quality of life,which is worthy of further clinical promotion and application.
NETL
NSTL
万方数据
